# O2MEDi

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/o2medi

- Industry: Pharmaceuticals
- Headquarters: Ulsan, South Korea
- Website: www.o2medi.com/
- Latest round: Seed (Nov 16, 2021)
- Investors on record: 2

## About

Founded in 2020 and based in Ulsan, South Korea, O2MEDi Inc. focuses on developing advanced photodynamic therapy products to combat challenging diseases, particularly drug-resistant cancers.O2MEDi Inc. specializes in innovative treatments utilizing photodynamic therapy technology. Founded in Ulsan, South Korea in 2020, the company has conducted one deal as of November 2021. The founder's previous entrepreneurial background is not publicly available, and there are no known pivots or changes in business strategy since its inception.O2MEDi specializes in the development of innovative photodynamic therapy (PDT) products aimed at treating challenging diseases, particularly resistant cancers such as pancreatic cancer. Their core technology employs iridium-based photosensitizers designed to generate reactive oxygen species (ROS) when activated by light, facilitating the targeted destruction of cancer cells that exhibit drug resistance. This technology overcomes the limitations of existing treatments, particularly in hypoxic environments where traditional methods are less effective. O2MEDi’s solutions are designed for healthcare professionals and institutions, with ongoing clinical trials and preclinical studies to validate their efficacy in treating various cancers. The geographical markets targeted by O2MEDi include South Korea, with plans to expand into international markets as their products advance towards commercialization.O2MEDi generates revenue through partnerships with research institutions and healthcare providers, focusing primarily on the preclinical and clinical stages of their product pipeline. Business transactions typically involve collaborative agreements for clinical trials and the development of therapeutic agents, with potential revenue streams derived from licensing agreements and product commercialization in the future. Their flagship technology addresses the specific needs of oncologists dealing with treatment-resistant cancers, positioning them favorably for future market penetration. As they advance their clinical trials and secure regulatory approvals, O2MEDi aims to establish a direct-to-consumer model as well as B2B relationships with hospitals and oncology centers for their photodynamic therapy products.In November 2021, O2MEDi Inc. raised an undisclosed amount in Seed funding from Creative Economy Innovation Center and SERIES VENTURES. The funding will be utilized for further development of their photodynamic therapy products, including upcoming launches designed specifically for treatment-resistant cancers. The company plans to expand its market reach beyond South Korea into international markets, with a timeline yet to be specified. Their strategy includes advancing clinical trials and securing necessary regulatory approvals to facilitate these expansion efforts.

## Funding rounds

- Seed, Nov 16, 2021 — Ulsan Creative Economy Innovation Center, Series Ventures

## Investors

- Ulsan Creative Economy Innovation Center (https://capitalatlas.ai/funds/ulsan-creative-economy-innovation-center) — Seed
- Series Ventures (https://capitalatlas.ai/funds/series-ventures) — Seed